FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2711-2712 December 21, 2006 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

Edited by Klaus-Michael Debatin and Simone Fulda. 1129 pp., in two volumes, illustrated. Weinheim, Germany, Wiley-VCH, 2006. $565. ISBN 3-527-31237-4.

Among the recent offering of new books regarding therapy that targets the apoptotic process, this two-volume work is distinctive because of its wide scope and depth. The contributors are all leading experts in their fields in Europe, North America, Australia, and Japan.

The chapters of the first volume have been grouped into 10 sections: "Death Receptor," "Mitochondria," "Effector Systems," "Bcl-2 Family," "IAPs [Inhibitor of Apoptosis Proteins]," "Survival Pathways," "Oncogenes/Tumor Suppressor Genes," "Modulators," "Lysosomes and Nonapoptotic Pathways," and "Phagocytosis/Clearance." This volume covers almost all stages of apoptotic cell death, starting from the initiation of apoptosis and progressing to its terminal phase. . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.